阿帕替尼在实体肿瘤治疗中的应用与研究进展

Progress on apatinib for solid tumors

血管生成在细胞生长的过程中具有重要作用,同时也是肿瘤发生的基础。因此,抑制肿瘤血管生成是抗肿瘤的有效途径。阿帕替尼是一种新型小分子抗血管生成抑制剂,通过特异性抑制血管内皮细胞生成因子-2(VEGFR-2)的酪氨酸激酶活性,从而达到抑制肿瘤血管生成,发挥抗肿瘤作用。阿帕替尼最初在胃癌治疗中取得成效,随后在乳腺癌、肺癌、肝癌以及软组织等肿瘤中亦发现了其应用前景。本文将阿帕替尼在多种实体肿瘤中的相关临床试验进行综述,使读者更加全面地认识阿帕替尼,为临床实践提供参考,并期望为恶性肿瘤患者的治疗带来一些新的选择。

Angiogenesis play an important role in the process of cell growth, and it is one of the basic characteristics of malignant tumors. So, antiangiogenesis is an effective way to anti-tumor. Apatinib is a novel small-molecule vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor. Through specific inhibition of vascular endotbelial cells factor-2 tyrosine kinase activity, apatinib plays antiangiogenic and antitumor roles. Apatinib has demonstrated encouraging anticancer activity across a broad range of malignancies, including gastric cancer, breast cancer, non-small cell lung cancer, hepatocarcinoma and soft tissue tumor etc. This paper will make a review of clinical trials of apatinib to some solid tumors and provides reference for clinical practice in therapeutic options for cancer patients.